Literature DB >> 15519283

Alzheimer's disease meets the ubiquitin-proteasome system.

Sungmin Song1, Yong-Keun Jung.   

Abstract

Ubiquitin-positive deposits are histopathologically found in patients with Alzheimer's disease (AD). It is not understood why ubiquitin is accumulated in intra- and extra-cellular deposits or how it is involved in AD pathogenesis. Interestingly, recent evidence, including studies of E2-25K/Hip-2, has elucidated the molecular mechanism of the ubiquitin-proteasome system (UPS) malfunction in AD. The neurotoxicity and proteasome inhibition by Abeta, a main cause of AD pathogenesis, are mediated by increased E2-25K/Hip-2 in the brains of patients with AD. Furthermore, E2-25K/Hip-2 is required for the neurotoxicity that is mediated by a ubiquitin B mutant (UBB+1), which is a potent inhibitor of proteasomes that is found in patients with AD. Intensive research is required to identify the components of the UPS that are involved in AD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519283     DOI: 10.1016/j.molmed.2004.09.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  21 in total

Review 1.  ATF4: a Novel Potential Therapeutic Target for Alzheimer's Disease.

Authors:  Na Wei; Ling-Qiang Zhu; Dan Liu
Journal:  Mol Neurobiol       Date:  2014-11-09       Impact factor: 5.590

2.  Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains.

Authors:  Victor P Andreev; Vladislav A Petyuk; Heather M Brewer; Yuliya V Karpievitch; Fang Xie; Jennifer Clarke; David Camp; Richard D Smith; Andrew P Lieberman; Roger L Albin; Zafar Nawaz; Jimmy El Hokayem; Amanda J Myers
Journal:  J Proteome Res       Date:  2012-05-17       Impact factor: 4.466

3.  Characterizing polyubiquitinated forms of the neurodegenerative ubiquitin mutant UBB+1.

Authors:  Michal Chojnacki; Daoning Zhang; Monika Talarowska; Piotr Gałecki; Janusz Szemraj; David Fushman; Mark A Nakasone
Journal:  FEBS Lett       Date:  2016-11-22       Impact factor: 4.124

4.  Destabilization of Rb by human papillomavirus E7 is cell cycle dependent: E2-25K is involved in the proteolysis.

Authors:  Kwang-Jin Oh; Anna Kalinina; Srilata Bagchi
Journal:  Virology       Date:  2009-11-10       Impact factor: 3.616

5.  Structure of full-length ubiquitin-conjugating enzyme E2-25K (huntingtin-interacting protein 2).

Authors:  Randall C Wilson; Ronny C Hughes; Justin W Flatt; Edward J Meehan; Joseph D Ng; Pamela D Twigg
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-04-24

6.  Genotype phenotype correlation of 30 patients with Smith-Magenis syndrome (SMS) using comparative genome hybridisation array: cleft palate in SMS is associated with larger deletions.

Authors:  J Andrieux; C Villenet; S Quief; S Lignon; S Geffroy; C Roumier; H de Leersnyder; M-C de Blois; S Manouvrier; B Delobel; B Benzacken; P Bitoun; T Attie-Bitach; S Thomas; S Lyonnet; M Vekemans; J-P Kerckaert
Journal:  J Med Genet       Date:  2007-04-27       Impact factor: 6.318

7.  Carboxyl terminus of heat-shock cognate 70-interacting protein degrades tau regardless its phosphorylation status without affecting the spatial memory of the rats.

Authors:  Y-J Zhang; Y-F Xu; X-H Liu; D Li; J Yin; Y-H Liu; X-Q Chen; J-Z Wang
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

8.  An antibody to the beta-secretase cleavage site on amyloid-beta-protein precursor inhibits amyloid-beta production.

Authors:  Rhian S Thomas; J Eryl Liddell; Lynne S Murphy; David M Pache; Emma J Kidd
Journal:  J Alzheimers Dis       Date:  2006-12       Impact factor: 4.472

Review 9.  Contribution of yeast models to neurodegeneration research.

Authors:  Clara Pereira; Cláudia Bessa; Joana Soares; Mariana Leão; Lucília Saraiva
Journal:  J Biomed Biotechnol       Date:  2012-07-15

10.  Mutation in E1, the ubiquitin activating enzyme, reduces Drosophila lifespan and results in motor impairment.

Authors:  Hsiu-Yu Liu; Cathie M Pfleger
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.